Comparison of the Influence of Different Skin Conditions on the Allergic Skin Reactivity to Epicutanous Allergen Exposure

The Objective is the determination of the allergic skin reactivity to epicutaneoulsy applied birch pollen allergen extract after skin preparation (microporation by P.L.E.A.S.E. Professional) and standard skin prick test. By using the standard prick test the stratum corneum is overcome by a single puncture (1 mm).

Micropores induced by P.L.E.A.S.E. Professional penetrate the stratum corneum less deep but with a higher density (five pores). It is therefore suggested that a skin preparation with micropores by P.L.E.A.S.E. Professional previously to the allergen contact may lead to a higher sensitivity. Less allergen might still elicit a skin reaction which won?t be seen by a conventional prick skin test. Whereas skin prick test may lead to true-negative (patient shows no allergic reaction on prick skin test but is an allergy sufferer in clinic), IgE-determination may lead to false-positives (patient is determined as allergy sufferer but has no clinical symptoms). So the sensitivity with micropores skin preparation by P.L.E.A.S.E. Professional could be a good compromise. The preparation of the skin with P.L.E.A.S.E. Professional leads to a better understanding of the influence of different types of skin injury patterns on the allergic skin reactivity. Namely, how important is the role of the exposed area, the depth of injury and the keratinocyte activation.

This will be checked in a late phase reaction evaluation.

Inclusion criteria

• Written informed consent,
• 18-65 years old (male or female),
• a positive clinical history for inhalant allergy presumably due to birch pollen,
• positive screening prick test (mean wheal diameter bigger or equal than 3mm) to birch pollen allergen solution,
• a mean wheal size of bigger or equal than 7mm2 obtained in the screening prick test with histamine dihydrochloride (10mg/ml)

Exclusion criteria

• Impaired in understanding the nature, meaning and scope of the study or incapable of giving written informed consent,
• enrolment into a clinical trial within last 4 weeks,
• pregnancy or nursing,
• positive skin reaction in the screening prick test to NaCl,
• currently suffering from allergy symptoms,
• history of systemic reactions to allergens,
• severe diseases influencing the results of the present study by discretion of the investigator,
• immunotherapy with the allergen preparation during the past two years,
• skin lesions and excessive hair-growth in the skin test areas,
• treatment with prohibited concomitant medications with the exception of medications with local effects which will not influence the results of the skin prick tests,
• known or suspected non-compliance, drug or alcohol abuse